In the last trading session, 1.12 million Perspective Therapeutics Inc (AMEX:CATX) shares changed hands as the company’s beta touched 1.44. With the company’s per share price at $13.35 changed hands at $0.78 or 6.21% during last session, the market valuation stood at $900.19M. CATX’s last price was a discount, traded about -42.7% off its 52-week high of $19.05. The share price had its 52-week low at $2.20, which suggests the last value was 83.52% up since then. When we look at Perspective Therapeutics Inc’s average trading volume, we note the 10-day average is 1.14 million shares, with the 3-month average coming to 914.25K.

Analysts gave the Perspective Therapeutics Inc (CATX) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 4 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended CATX as a Hold, 4 felt it is a Buy and 0 rated the stock as Underweight. Perspective Therapeutics Inc’s EPS for the current quarter is expected to be -0.22.

Perspective Therapeutics Inc (AMEX:CATX) trade information

Instantly CATX was in green as seen at the end of in last trading. With action 9.16%, the performance over the past five days has been green. The company’s shares are showing year-to-date upside of 232.09%, with the 5-day performance at 9.16% in the green. However, in the 30-day time frame, Perspective Therapeutics Inc (AMEX:CATX) is -14.31% down. Looking at the short shares, we see there were 7.14 million shares sold at short interest cover period of 9.7 days.

The consensus price target for the stock as assigned by Wall Street analysts is 20, meaning bulls need an upside of 33.25% from its current market value. According to analyst projections, CATX’s forecast low is 3 with 24 as the target high. To hit the forecast high, the stock’s price needs a -79.78% plunge from its current level, while the stock would need to tank 77.53% for it to hit the projected low.

Perspective Therapeutics Inc (CATX) estimates and forecasts

Data shows that the Perspective Therapeutics Inc share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot 4.30% over the past 6 months, a 38.57% in annual growth rate that is considerably higher than the industry average of 20.30%. Year-over-year growth is forecast to reach -86.60% down from the last financial year.

Consensus estimates given by 6 financial analysts project the company’s revenue in the current quarter to hit an average of 140k. 6 analysts are of the opinion that Perspective Therapeutics Inc’s revenue for the current quarter will be 140k. The company’s revenue for the corresponding quarters a year ago was 2.19M and 2.03M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at -93.60%. The estimates for the next quarter sales put growth at -93.10%.

Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -7.69%. The 2024 estimates are for Perspective Therapeutics Inc earnings to increase by 47.98%.

CATX Dividends

Perspective Therapeutics Inc is expected to release its next quarterly earnings report in November.

Perspective Therapeutics Inc (AMEX:CATX)’s Major holders

If we look at who the major shareholders are, we find that insiders hold 20.43% of Perspective Therapeutics Inc shares while 57.90% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 72.76%.